Anifrolumab monotherapy associated with lower odds of hospitalization and antibiotic use compared with conventional immunosuppressants ...

Transferrin saturation and ferritin thresholds recommended for guiding iron therapy; IV iron preferred over oral iron for hemodialysis recipients.

Gap is 5.6 years shorter than the overall Medicaid population and 13.8 years shorter than the US general population.

All participating US comprehensive cancer centers report a shortage of at least 1 drug with 20% reporting 5 or more ...

The sNDA approval provides clinicians with the first FDA-cleared photodynamic therapy for skin cancer, backed by phase 3 trial data demonstrating superior clinical and histologic clearance.

Phase 3 COVER DFUS II trial data show the autologous therapy plus standard of care significantly improves wound closure rates at 12 weeks.

The application is supported by phase 2 APEX trial data, which demonstrated a 65% objective response rate among patients with advanced disease.

SAMA and SABA + SAMA use associated with increased risk for heart failure, arrhythmia, and mortality versus no use ...

Progressive decrease in adjusted odds of hospitalization seen in association with vaccination versus no vaccination.

Labeling update reduces required post-infusion monitoring time for initial doses from 22 to 24 hours to 6 to 8 hours in patients with extensive-stage small cell lung cancer.

The FDA is reviewing an sNDA to extend the duration of use for the hormone-free Miudella intrauterine system from 3 years to up to 6 years.

The FDA has expanded the indication for leniolisib to include younger pediatric patients with activated phosphoinositide 3-kinase delta syndrome (APDS).